Bristol Myers Squibb Approval: The European Commission approved Breyanzi for treating adult patients with relapsed or refractory mantle cell lymphoma, marking its fourth approval in Europe for various lymphomas.
Clinical Trial Results: The approval is based on the TRANSCEND NHL 001 trial, showing an 82.7% response rate and 71.6% complete response rate among patients treated with Breyanzi.
Market Impact and Pipeline Expansion: Bristol Myers is focusing on expanding its drug pipeline due to challenges from generics affecting its legacy products, with recent share gains following positive news from Bayer's stroke prevention candidate.
Discontinuation of Librexia Study: Bristol Myers and Johnson & Johnson halted the Librexia study for milvexian after an interim analysis indicated it would not meet efficacy endpoints, but other studies for milvexian will continue as planned.
Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 218.490
Low
190.00
Averages
218.50
High
240.00
Current: 218.490
Low
190.00
Averages
218.50
High
240.00
Guggenheim
Vamil Divan
Buy
maintain
$227 -> $240
2026-01-23
New
Reason
Guggenheim
Vamil Divan
Price Target
$227 -> $240
AI Analysis
2026-01-23
New
maintain
Buy
Reason
Guggenheim analyst Vamil Divan raised the firm's price target on Johnson & Johnson to $240 from $227 and keeps a Buy rating on the shares after the company reported "solid" Q4 results and provided initial 2026 guidance that was slightly ahead of sell-side estimates. Following the quarter, the firm is making several adjustments to its model, including raising near-term Tremfya estimates, accelerating Stelara erosion, and raising estimates for multiple newer products, says the analyst, who continues to identify J&J as a Top Picks in the large cap biopharma sector.
BofA
Jason Gerberry
Neutral
maintain
$220 -> $221
2026-01-22
New
Reason
BofA
Jason Gerberry
Price Target
$220 -> $221
2026-01-22
New
maintain
Neutral
Reason
BofA analyst Jason Gerberry raised the firm's price target on Johnson & Johnson to $221 from $220 and keeps a Neutral rating on the shares. The firm "modestly" increased its 2026 sales and EPS estimates following J&J's "solid" Q4 report, but thinks J&J's premium multiple "encapsulates the current consensus growth outlook" and notes that it is more cautious on the new product cycle.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for JNJ
Unlock Now
Goldman Sachs
Asad Haider
Buy
maintain
$240 -> $250
2026-01-22
New
Reason
Goldman Sachs
Asad Haider
Price Target
$240 -> $250
2026-01-22
New
maintain
Buy
Reason
Goldman Sachs analyst Asad Haider raised the firm's price target on Johnson & Johnson to $250 from $240 and keeps a Buy rating on the shares. The setup is strong for another strong year with ongoing momentum in Innovative Medicine and MedTech, both of which demonstrated better-than-expected Q4 trends ahead of tailwinds in 2026 with multiple new product cycles continuing to unfold, the analyst tells investors in a research note.
Stifel
Rick Wise
Hold
maintain
$205 -> $220
2026-01-22
New
Reason
Stifel
Rick Wise
Price Target
$205 -> $220
2026-01-22
New
maintain
Hold
Reason
Stifel analyst Rick Wise raised the firm's price target on Johnson & Johnson to $220 from $205 and keeps a Hold rating on the shares following the company's Q4 sales outperformance and above-consensus initial 2026 guidance.
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
